First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis

Sanet Torres-Torres, Angela L. Myers, J. Michael Klatte, Eric E. Rhoden, M. Steven Oberste, Marc S. Collett, Russell J. McCulloh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalPediatric Infectious Disease Journal
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Investigational Drugs
Enterovirus
Antiviral Agents
Poliovirus
Infection
Neonatal Sepsis
Therapeutics

Keywords

  • Coxsackievirus
  • Neonatal enterovirus infection
  • Pocapavir

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis. / Torres-Torres, Sanet; Myers, Angela L.; Klatte, J. Michael; Rhoden, Eric E.; Oberste, M. Steven; Collett, Marc S.; McCulloh, Russell J.

In: Pediatric Infectious Disease Journal, Vol. 34, No. 1, 01.01.2015, p. 52-54.

Research output: Contribution to journalArticle

Torres-Torres, Sanet ; Myers, Angela L. ; Klatte, J. Michael ; Rhoden, Eric E. ; Oberste, M. Steven ; Collett, Marc S. ; McCulloh, Russell J. / First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis. In: Pediatric Infectious Disease Journal. 2015 ; Vol. 34, No. 1. pp. 52-54.
@article{b3d594bb4f0f4df4a489d426225ff970,
title = "First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis",
abstract = "Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.",
keywords = "Coxsackievirus, Neonatal enterovirus infection, Pocapavir",
author = "Sanet Torres-Torres and Myers, {Angela L.} and Klatte, {J. Michael} and Rhoden, {Eric E.} and Oberste, {M. Steven} and Collett, {Marc S.} and McCulloh, {Russell J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/INF.0000000000000497",
language = "English (US)",
volume = "34",
pages = "52--54",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis

AU - Torres-Torres, Sanet

AU - Myers, Angela L.

AU - Klatte, J. Michael

AU - Rhoden, Eric E.

AU - Oberste, M. Steven

AU - Collett, Marc S.

AU - McCulloh, Russell J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.

AB - Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.

KW - Coxsackievirus

KW - Neonatal enterovirus infection

KW - Pocapavir

UR - http://www.scopus.com/inward/record.url?scp=84926217187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926217187&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000000497

DO - 10.1097/INF.0000000000000497

M3 - Article

C2 - 25229269

AN - SCOPUS:84926217187

VL - 34

SP - 52

EP - 54

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 1

ER -